Changes in this receptor are linked to some types of type 2 diabetes
Tara *Based on internal survey 416 GLP-1 users in 2025 **Based on survey responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/tirzepatide for weight loss within the WW Clinic Program and participating in the GLP-1 companion nutrition program
Use can trigger sanctions independent of any legal question
Participants also lost on average about 11.5% to 15.3% of body weight on retatrutide, versus 2.6% with the placebo
for the US market, orally administered semaglutide was found to be cost effective in comparison to dulaglutide, exenatide, liraglutide and lixisenatide
Adding tesamorelin may provide incremental benefits for visceral fat and muscle preservation, but those benefits come with significant unknown risks